Duopharma Biotech Bhd (7148) - Total Liabilities
Based on the latest financial reports, Duopharma Biotech Bhd (7148) has total liabilities worth RM689.10 Million MYR (≈ $173.01 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 7148 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Duopharma Biotech Bhd - Total Liabilities Trend (2006–2025)
This chart illustrates how Duopharma Biotech Bhd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Duopharma Biotech Bhd's balance sheet.
Duopharma Biotech Bhd Competitors by Total Liabilities
The table below lists competitors of Duopharma Biotech Bhd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sonda S.A
SN:SONDA
|
Chile | CL$873.83 Billion |
|
PAM Mineral Tbk PT
JK:NICL
|
Indonesia | Rp138.61 Billion |
|
Jinpu Landscape Architecture Co.Ltd.
SHE:301098
|
China | CN¥1.91 Billion |
|
Taiga Building Products Ltd.
TO:TBL
|
Canada | CA$284.53 Million |
|
Brooge Holdings Ltd
NASDAQ:BROG
|
USA | $429.22 Million |
|
Habco Trans Maritima
JK:HATM
|
Indonesia | Rp272.19 Billion |
|
Minfeng Special Paper Co Ltd
SHG:600235
|
China | CN¥1.49 Billion |
|
Infotel SA
PA:INF
|
France | €127.17 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down Duopharma Biotech Bhd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Duopharma Biotech Bhd balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.91 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Duopharma Biotech Bhd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Duopharma Biotech Bhd (2006–2025)
The table below shows the annual total liabilities of Duopharma Biotech Bhd from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | RM690.68 Million ≈ $173.41 Million |
+3.42% |
| 2024-12-31 | RM667.85 Million ≈ $167.67 Million |
+1.49% |
| 2023-12-31 | RM658.01 Million ≈ $165.21 Million |
+16.11% |
| 2022-12-31 | RM566.70 Million ≈ $142.28 Million |
+4.92% |
| 2021-12-31 | RM540.13 Million ≈ $135.61 Million |
+30.27% |
| 2020-12-31 | RM414.61 Million ≈ $104.10 Million |
+6.30% |
| 2019-12-31 | RM390.05 Million ≈ $97.93 Million |
+9.77% |
| 2018-12-31 | RM355.34 Million ≈ $89.21 Million |
+57.66% |
| 2017-12-31 | RM225.38 Million ≈ $56.58 Million |
+8.90% |
| 2016-12-31 | RM206.95 Million ≈ $51.96 Million |
+12.64% |
| 2015-12-31 | RM183.73 Million ≈ $46.13 Million |
+536.91% |
| 2014-12-31 | RM28.85 Million ≈ $7.24 Million |
+25.41% |
| 2013-12-31 | RM23.00 Million ≈ $5.78 Million |
-16.43% |
| 2012-12-31 | RM27.53 Million ≈ $6.91 Million |
-16.77% |
| 2011-12-31 | RM33.08 Million ≈ $8.30 Million |
-14.34% |
| 2010-12-31 | RM38.61 Million ≈ $9.69 Million |
+26.07% |
| 2009-12-31 | RM30.63 Million ≈ $7.69 Million |
+54.46% |
| 2008-12-31 | RM19.83 Million ≈ $4.98 Million |
+51.11% |
| 2007-12-31 | RM13.12 Million ≈ $3.29 Million |
-3.36% |
| 2006-12-31 | RM13.58 Million ≈ $3.41 Million |
-- |
About Duopharma Biotech Bhd
Duopharma Biotech Berhad, together with its subsidiaries, researches, develops, manufactures, markets, sells, imports, and distributes pharmaceutical products and medicines in Malaysia and internationally. It offers consumer healthcare products, including vitamins, minerals, and supplements under the Flavettes, PROVITON, PROVITON STR, CHAMPS, and Naturalle brand names; analgesics and antitussives… Read more